文章:
AP-1:肿瘤发生的双刃剑
AP-1: a double-edged sword in tumorigenesis
原文发布日期:2003-11-01
DOI: 10.1038/nrc1209
类型: Review Article
开放获取: 否
要点:
- AP-1 is a dimeric transcription factor that contains members from the JUN, FOS, ATF and MAF protein families.
- AP-1 activity can be regulated by dimer composition, transcription, post-translational modification and interactions with other proteins.
- Two of the components of AP-1 — c-JUN and c-FOS — were first identified as viral oncoproteins, so their role in tumorigenesis is well established.
- However, some JUN and FOS family proteins can suppress tumour formation. The decision as to whether AP-1 is oncogenic or anti-oncogenic depends on the cell type and its differentiation state, tumour stage and the genetic background of the tumour.
- AP-1 can exert its oncogenic or anti-oncogenic effects by regulating genes involved in cell proliferation, differentiation, apoptosis, angiogenesis and tumour invasion.
- AP-1 might be a good target for anticancer therapy.
要点翻译:
- AP-1是一种二聚体转录因子,其成员包含JUN、FOS、ATF和MAF蛋白家族。
- AP-1的活性可通过二聚体组成、转录、翻译后修饰以及与其他蛋白质的相互作用进行调控。
- AP-1的两个组分——c-JUN和c-FOS——最初被鉴定为病毒癌蛋白,因此它们在肿瘤发生中的作用已得到充分确认。
- 然而,部分JUN和FOS家族蛋白可抑制肿瘤形成。AP-1发挥促癌还是抑癌作用取决于细胞类型及其分化状态、肿瘤分期和肿瘤的遗传背景。
- AP-1可通过调控参与细胞增殖、分化、凋亡、血管生成和肿瘤侵袭的基因来发挥其促癌或抑癌效应。
- AP-1可能成为抗癌治疗的良好靶点。
英文摘要:
The AP-1 transcription factor is a dimeric complex that contains members of the JUN, FOS, ATF and MAF protein families. AP-1 proteins are primarily considered to be oncogenic, but recent studies have challenged this view — some AP-1 proteins, such as JUNB and c-FOS, have been shown to have tumour-suppressor activity. Here, we focus on the JUN and FOS proteins and aim to offer a new perspective on the molecular mechanisms that regulate the oncogenic and anti-oncogenic effects of AP-1 in tumour development.
摘要翻译:
AP-1转录因子是一种包含JUN、FOS、ATF和MAF蛋白家族成员的二聚体复合物。AP-1蛋白传统上被视为致癌因子,但最新研究挑战了这一观点——某些AP-1蛋白(如JUNB和c-FOS)已被证实具有抑瘤活性。本文聚焦JUN与FOS蛋白,旨在从分子机制层面为AP-1在肿瘤发生中的双重致癌与抑癌效应提供新视角。
原文链接:
AP-1: a double-edged sword in tumorigenesis